Abstract
Background: Recently, a novel point-of-care test (POCT) for N-terminal proBNP (NT-proBNP) has been introduced (Cardiac proBNP (R), Roche). Aim: The aim was to compare the novel POCT for NT-proBNP with the established POCT for BNP. Methods: NT-proBNP and BNP were assessed in 222 individuals with chronic heart failure (n = 151) or controls (n = 71) with both POCTs. Results: NT-proBNP and BNP were ...
Abstract
Background: Recently, a novel point-of-care test (POCT) for N-terminal proBNP (NT-proBNP) has been introduced (Cardiac proBNP (R), Roche). Aim: The aim was to compare the novel POCT for NT-proBNP with the established POCT for BNP. Methods: NT-proBNP and BNP were assessed in 222 individuals with chronic heart failure (n = 151) or controls (n = 71) with both POCTs. Results: NT-proBNP and BNP were closely correlated upon regression analysis (r = 0.93; p < 0.01). NT-proBNP and BNP were both correlated with ejection fraction and New York Heart Association stage. Receiver operating characteristic analysis yielded satisfying and equivalent predictive values for the detection of left ventricular dysfunction (ejection fraction <40%; NT-proBNP: area under the curve 0.97; BNP: area under the curve 0.96; p > 0.05) and presence of New York Heart Association stage >2 (area under the curve 0.92 vs 0.91 for NT-proBNP and BNP, respectively; p > 0.05). Conclusion: The NT-proBNP POCT allows biochemical detection of heart failure with satisfactory predictive values, is equivalent to the BNP POCT and will improve near-patient testing.
Altmetric